A. Ling

发表

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists

C. Behrens, L. B. Knudsen, C. L. Brand, 2007 .

Approaches to glucagon receptor antagonists

A. Ling, J. I. Wasserman, 2003 .

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.

A. Kuki, Michael D. Johnson, D. Murphy, 2002, Journal of medicinal chemistry.

Small-molecule glucagon receptor antagonists

A. Ling, 2002 .

New beta-alanine derivatives are orally available glucagon receptor antagonists.

C. Behrens, L. B. Knudsen, C. L. Brand, 2007, Journal of medicinal chemistry.

Human glucagon receptor antagonists based on alkylidene hydrazides.

A. Kuki, D. Murphy, A. Polinsky, 2002, Bioorganic & medicinal chemistry letters.

Identification of alkylidene hydrazides as glucagon receptor antagonists.

A. Kuki, D. Murphy, A. Polinsky, 2001, Journal of medicinal chemistry.

Human Glucagon Receptor Antagonists Based on Alkylidene Hydrazides

A. Ling, 2002 .

Neuropeptide Y receptor antagonists

A. Ling, 1999 .

Expert Opinion on Therapeutic Patents

A. Ling, 1999 .